MariMed Inc. Reports Fourth‑Quarter and Full‑Year 2025 Financial Results

MariMed Inc. (OTC: MRMD) released its financial results for the fourth quarter and the full year ended 31 December 2025 on 11 March 2026. The company, which specializes in the design, development, operation, funding, and optimization of medical cannabis cultivation and distribution facilities in Massachusetts and nationwide, reported a continuation of its operating losses despite modest revenue growth.

Earnings Per Share

  • Fourth‑quarter loss per share: –$0.01, a reduction from the previous quarter’s loss of –$0.02 per share.
  • Full‑year loss per share: –$0.03, unchanged from the prior year’s –$0.03 per share.

Analysts surveyed by Finanzen.net and Benzinga anticipated a fourth‑quarter loss of –$0.01 per share, aligning with the company’s actual figure.

Revenue

  • Fourth‑quarter revenue: $40.4 million, an increase of 3.46 % over the same period a year earlier. The previous year’s quarter generated $39.0 million.
  • Full‑year revenue: $161.6 million, up from $158.0 million in 2024.

The revenue growth reflects incremental sales from the company’s medical‑cannabis production centers and dispensaries, although the overall scale remains modest relative to industry peers.

Market Context

MariMed’s market capitalization stood at approximately $32.4 million, with a closing share price of $0.081 on 9 March 2026. The 52‑week high and low were $0.23 and $0.067, respectively, indicating significant volatility.

Outlook

While the company maintained its loss profile, the modest revenue expansion suggests a gradual build in operational capacity. Investors and analysts will likely focus on the company’s ability to convert growing sales into profitability in the coming quarters.

Sources: Global News Wire, CEO.ca, Benzinga, Finanzen.net, AllPennyStocks.